Form 4: Raymond Dwek Executes Share Tracking Awards Under 10b5-1 Plan
SEC Form 4
Director Raymond Dwek exercised share tracking awards of United Therapeutics Corporation under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Raymond Dwek, a director of United Therapeutics Corporation, executed share tracking awards on April 15, 2024.
- The transaction involved the exercise of 3,000 share tracking awards at a price of $88.03.
- This was done under a pre-arranged Rule 10b5-1 trading plan established on November 27, 2023.
- The share tracking awards are non-dilutive, cash-settled stock appreciation rights that can only be settled in cash and not converted into common stock.
- Following the transaction, Dwek directly owns 1,750 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 plan suggests a proactive approach to compliance with insider trading regulations.
Key Dates
| Date | Description |
|---|---|
| 06/26/2015 | Date share tracking award was exercisable |
| 11/27/2023 | Date of establishment of Rule 10b5-1 trading plan |
| 04/15/2024 | Date of transaction (exercise of share tracking awards) |
| 06/26/2024 | Expiration date of share tracking award |
| 04/16/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.